Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Trial design:
This Phase III, investigator-driven, randomised, placebo-controlled efficacy and safety study
will compare the effects of Sitagliptin in combination with granulocyte-colony stimulating
factor (Lenograstim, G-CSF) on the improvement of myocardial function in patients undergoing
routine percutaneous coronary revascularisation for acute myocardial infarction (time from
onset of infarction to intervention 2 to 24 hours). The primary objective of this study is to
compare between a treatment of G-CSF plus Sitagliptin, (G-CSF/Sitagliptin treatment group,
n=87) versus Placebo (control treatment group, n=87) in change of global myocardial function
from baseline to 6 months of follow-up.